Your browser doesn't support javascript.
loading
Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain.
Baerwald, Christoph; Stemmler, Edgar; Gnüchtel, Sixten; Jeromin, Katharina; Fritz, Björn; Bernateck, Michael; Adolf, Daniela; Taylor, Peter C; Baron, Ralf.
Afiliación
  • Baerwald C; Zentrum für Seltene Erkrankungen, University Hospital Leipzig, Leipzig, Germany cbaerwald@outlook.de.
  • Stemmler E; AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany.
  • Gnüchtel S; AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany.
  • Jeromin K; AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany.
  • Fritz B; AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany.
  • Bernateck M; Center for Rheumatology & Pain-Medicine, Hannover, Germany.
  • Adolf D; StatConsult GmbH, Magdeburg, Germany.
  • Taylor PC; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK.
  • Baron R; Department of Neurology, University Hospital Schleswig Holstein, Kiel, Germany.
Ann Rheum Dis ; 2024 May 30.
Article en En | MEDLINE | ID: mdl-38816064
ABSTRACT

OBJECTIVES:

To determine the proportion of patients with rheumatoid arthritis (RA) with severe persisting pain and to identify predictive factors despite treatment-controlled disease activity.

METHODS:

This prospective multicentre study included outpatients with RA scheduled for escalation of anti-inflammatory treatment due to active disease and severe pain (Disease Activity Score 28 (DAS28)>3.2 and Visual Analogue Scale (VAS)>50). At week 24, patients were stratified into reference group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score<50), non-responders (DAS28 improvement≤1.2 and DAS28>3.2, regardless of VAS pain score) and persisting pain group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score≥50). The former two subgroups ended the study at week 24. The latter continued until week 48. Demographic data, DAS28-C reactive protein, VAS for pain, painDETECT Questionnaire (PD-Q) to identify neuropathic pain (NeP) and the Pain Catastrophising Scale were assessed and tested for relation to persisting pain.

RESULTS:

Of 567 patients, 337 (59.4%) were classified as reference group, 102 (18.0%) as non-responders and 128 (22.6%) as patients with persisting pain. 21 (8.8%) responders, 28 (35.0%) non-responders and 27 (26.5%) persisting pain patients tested positive for NeP at week 24. Pain catastrophising (p=0.002) and number of tender joints (p=0.004) were positively associated with persisting pain at week 24. Baseline PD-Q was not related to subsequent persisting pain.

CONCLUSIONS:

Persisting and non-nociceptive pain occur frequently in RA. Besides the potential involvement of NeP, pain catastrophising and a higher number of tender joints coincide with persisting pain.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Rheum Dis Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Rheum Dis Año: 2024 Tipo del documento: Article País de afiliación: Alemania